SGBI
Sangui Biotech International, Inc. [SGBI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SGBI Stock Summary
Top 10 Correlated Stocks
SGBI
In the News
SGBI Financial details
Company Rating
Neutral
Market Cap
733.61K
Income
-165.12K
Revenue
80.86K
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
10 May 2021
P/E
-3.11
Forward P/E
-
PEG
0.93
P/S
8.65
P/B
-1.72
P/C
-
P/FCF
-29.64
Quick Ratio
0.03
Current Ratio
0.04
Debt / Equity
-2.35
LT Debt / Equity
-0.07
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-108.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-2.15%
Revenue Q/Q
75.94%
EPS Q/Q
-50%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-220%
ROE
67%
ROC
0.07%
Gross Margin
100%
Oper. Margin
-95%
Profit Margin
-278%
Payout
-
Shs Outstand
209.9M
Shs Float
182.54M
-
-
-
-
Target Price
-
52W Range
0.002-0.02
52W High
-
52W Low
-
RSI
43.39
Rel Volume
0.03
Avg Volume
3.01K
Volume
100
Perf Week
0%
Perf Month
3.57%
Perf Quarter
-
Perf Half Y
5.45%
-
-
-
-
Beta
0.198
-
-
Volatility
0%, 0%
Prev Close
-16.91%
Price
0.0029
Change
-16.91%
SGBI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-06-30
| Metric | History | 2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 2.82M | 2.78M | 2.92M | 4.51M | 2.09M | |
| Enterprise value | 3.05M | 3.23M | 3.59M | 5.3M | 2.88M | |
| P/E ratio | -13.99 | -8.77 | -13.33 | -19.12 | 124.21 | |
| Price to sales ratio | 36.59 | 31.58 | 100.82 | 68.81 | 30.15 | |
| POCF ratio | -11.12 | -8.77 | -17.31 | -30.94 | -14.85 | |
| PFCF ratio | -11.12 | -8.77 | -17 | -30.94 | -14.85 | |
| P/B Ratio | 10.41 | 56.49 | -35.17 | -20.19 | -8.72 | |
| PTB ratio | 10.41 | 56.49 | -35.17 | -20.19 | -8.72 | |
| EV to sales | 39.49 | 36.71 | 124.28 | 80.85 | 41.63 | |
| Enterprise value over EBITDA | -15.74 | -9.57 | -19.94 | -35.27 | -23.57 | |
| EV to operating cash flow | -12.01 | -10.19 | -21.34 | -36.36 | -20.51 | |
| EV to free cash flow | -12.01 | -10.19 | -20.96 | -36.36 | -20.51 | |
| Earnings yield | -0.07 | -0.11 | -0.08 | -0.05 | 0.01 | |
| Free cash flow yield | -0.09 | -0.11 | -0.06 | -0.03 | -0.07 | |
| Debt to equity | 0.9 | 9.72 | -8.37 | -3.67 | -3.45 | |
| Debt to assets | 2.39 | 6.06 | 5.53 | 6.11 | 6.31 | |
| Net debt to EBITDA | -1.15 | -1.34 | -3.76 | -5.25 | -6.5 | |
| Current ratio | 0.23 | 0.12 | 0.06 | 0.07 | 0.07 | |
| Interest coverage | -25.04 | -28.89 | -12.87 | -8.4 | -7.2 | |
| Income quality | 1.26 | 0.93 | 0.85 | 0.72 | 2.22 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.4 | 4.53 | 6.94 | 3.17 | 2.88 | |
| Research and developement to revenue | 0.3 | 0.31 | 0.29 | 0.13 | 0.12 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.02 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.11 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0.29 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.01 | 0 | 0 | 0.01 | 0 | |
| ROIC | -0.38 | -0.59 | -0.29 | -0.26 | 0.06 | |
| Return on tangible assets | -1.98 | -4.01 | -1.75 | -1.76 | 0.13 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | -351.14K | -591.99K | -742.79K | -888.04K | -867.91K | |
| Tangible asset value | -351.14K | -591.99K | -729.88K | -875.33K | -894.96K | |
| Net current asset value | -351.14K | -591.99K | -806.51K | -942.78K | -958.04K | |
| Invested capital | 0.9 | 9.72 | -8.37 | -3.67 | -3.45 | |
| Average receivables | 34.22K | 50.18K | 31.05K | 22.47K | 25.15K | |
| Average payables | 189.3K | 176.94K | 141.7K | 123.28K | 127.85K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 275.87 | 174.4 | 253.13 | 138.45 | 134.09 | |
| Days payables outstanding | 1.12M | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.32 | 2.09 | 1.44 | 2.64 | 2.72 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.74 | -6.44 | 2.64 | 1.06 | -0.07 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q3
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 3.98M | 2.04M | 2.41M | 925.9K | 965.8K | |
| Enterprise value | 4.79M | 2.84M | 3.17M | 1.75M | 1.79M | |
| P/E ratio | -66.9 | 16.73 | 9.38 | -1.3 | -2.95 | |
| Price to sales ratio | 221.52 | 194.39 | 58.85 | 87.13 | 51.66 | |
| POCF ratio | -160.53 | -54.69 | -93.99 | 188.96 | 3.85K | |
| PFCF ratio | -160.53 | -54.69 | -93.99 | 188.96 | 3.85K | |
| P/B Ratio | -16.68 | -8.54 | -11.64 | -2.94 | -2.73 | |
| PTB ratio | -16.68 | -8.54 | -11.64 | -2.94 | -2.73 | |
| EV to sales | 266.65 | 270.03 | 77.3 | 164.4 | 95.89 | |
| Enterprise value over EBITDA | -147.25 | -211.66 | -274.78 | -76.8 | -99.37 | |
| EV to operating cash flow | -193.24 | -75.97 | -123.46 | 356.55 | 7.14K | |
| EV to free cash flow | -193.24 | -75.97 | -123.46 | 356.55 | 7.14K | |
| Earnings yield | 0 | 0.01 | 0.03 | -0.19 | -0.08 | |
| Free cash flow yield | -0.01 | -0.02 | -0.01 | 0.01 | 0 | |
| Debt to equity | -3.68 | -3.45 | -3.68 | -2.64 | -2.35 | |
| Debt to assets | 4.71 | 6.31 | 5.99 | 8.38 | 9.36 | |
| Net debt to EBITDA | -24.93 | -59.29 | -65.59 | -36.1 | -45.84 | |
| Current ratio | 0.12 | 0.07 | 0.08 | 0.04 | 0.04 | |
| Interest coverage | -6.24 | -8.87 | -3.2 | -5.4 | -4.4 | |
| Income quality | 1.6 | 3.81 | -1.03 | -0.05 | -0.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.46 | 5.33 | 1.33 | 3.41 | 2.18 | |
| Research and developement to revenue | 0.11 | 0.2 | 0.06 | 0.16 | 0.04 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0.01 | 0 | |
| ROIC | 0 | 0.23 | -0.07 | -0.08 | -0.09 | |
| Return on tangible assets | -0.08 | 0.23 | 0.5 | -1.8 | -0.92 | |
| Graham Net | 0 | 0 | 0 | 0 | -0.01 | |
| Working capital | -861.21K | -867.91K | -838.16K | -946.3K | -988.12K | |
| Tangible asset value | -891.91K | -894.96K | -861.5K | -970.11K | -1.01M | |
| Net current asset value | -963.69K | -958.04K | -915.84K | -1.02M | -1.06M | |
| Invested capital | -3.68 | -3.45 | -3.68 | -2.64 | -2.35 | |
| Average receivables | 30.43K | 27.47K | 42.54K | 45.23K | 29.42K | |
| Average payables | 129.17K | 128.47K | 139.06K | 152.71K | 166.01K | |
| Average inventory | 0 | 0 | 0 | -7.96K | -7.96K | |
| Days sales outstanding | 148.01 | 217.79 | 130.88 | 260.83 | 135.02 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.61 | 0.41 | 0.69 | 0.35 | 0.67 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.06 | -0.13 | -0.31 | 0.57 | 0.23 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SGBI Frequently Asked Questions
What is Sangui Biotech International, Inc. stock symbol ?
Sangui Biotech International, Inc. is a DE stock and trading under the symbol SGBI
What is Sangui Biotech International, Inc. stock quote today ?
Sangui Biotech International, Inc. stock price is $0.0029 today.
Is Sangui Biotech International, Inc. stock public?
Yes, Sangui Biotech International, Inc. is a publicly traded company.
Company Profile
- Volume Average 3.01K
- Market Capitalization 733.61K
- CEO Mr. Thomas Striepe
- Headquarters Hamburg,DE
- IPO Date 1997-03-27
-
Website
https://www.sanguibiotech.com 
Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
